AI assistant
RIGEL PHARMACEUTICALS INC — Director's Dealing 2025
Feb 1, 2025
32801_dirs_2025-01-31_8cef96f4-bbc2-4d5e-b9a9-002a44c3bb02.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2025-01-29
Reporting Person: Schorno Dean L (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-29 | Common Stock | A | 19717 | — | Acquired | 61005 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-29 | Employee Stock Option (Right to Buy) | $22.49 | A | 14788 | Acquired | 2035-01-29 | Common Stock (14788) | Direct |
Footnotes
F1: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026.
F2: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F3: Includes 999 shares acquired under the Issuer's stock purchase plan.
F4: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period.